天眼查App显示,2025年5月9日,“化学修饰的糖胺聚糖类衍生物的抗病毒用途”正式进入专利公布阶段。申请人为深圳市海普瑞药业集团股份有限公司,该项医学专利涉及抗病毒药物的研发与应用。据专利信息显示,该活性化合物对多种冠状病毒具有显著抑制活性,EC50值小,同时对正常细胞毒副作用低(细胞毒性CC50>100μM),出血风险低,安全性高。此外,该化合物还具有显著优化的药代动力学性质,生物利用度高,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.